B-cell activating factor (BAFF) expression is associated with Crohn's disease and can serve as a potential prognostic indicator of disease response to Infliximab treatment
Several studies correlated elevated B-cell activating factor (BAFF) levels and its polymorphisms (SNPs) in patients with autoimmunity. Limited data existed regarding the role of BAFF in Crohn's Disease (CD) susceptibility and/or treatment response to infliximab.
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Nikolaos-Panagiotis Andreou, Evangelia Legaki, Nikolas Dovrolis, Nikola Boyanov, Konstantinos Georgiou, Kalliopi Gkouskou, Maria Gazouli Tags: Alimentary Tract Source Type: research
More News: Crohn's Disease | Gastroenterology | Inflammatory Bowel Disease | Liver | Liver Disease | Remicade | Study | Urology & Nephrology